Definium Therapeutics Overview
Definium Therapeutics Target Price
Analysts' 12-month price predictions for DFTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$44.19
Average Target Price
$48.50
9.8% upside
9.8% upside10 analysts in the last 4 months
High: $60 | Low: $30
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-30 | Canaccord Genuity | $58 | 31.3% upside |  |
| 2026-06-23 | NeedhamAmi Fadia | $50 | 13.1% upside | |
| 2026-06-22 | Canaccord Genuity | $60 | 35.8% upside | |
| 2026-06-22 | Oppenheimer | $60 | 35.8% upside | |
| 2026-06-22 | Leerink PartnersMarc Goodman | $52 | 17.7% upside | |
| 2026-05-08 | Piper SandlerDavid Amsellem | $48 | 8.6% upside | |
| 2026-04-23 | Oppenheimer | $40 |  9.5% downside | |
| 2026-04-16 | Stifel NicolausPaul Matteis | $30 | 32.1% downside | |
| 2026-04-16 | Canaccord GenuitySumant Kulkarni | $38 | 14% downside | |
| 2026-04-10 | Piper Sandler | $49 | 10.9% upside | |
| 2026-02-23 | Wolfe Research | $25 | 43.4% downside | |
| 2026-01-29 | Jefferies | $30 | 32.1% downside | |
| 2026-01-29 | Robert W. Baird | $37 | 16.3% downside | |
| 2026-01-23 | RBC Capital | $36 | 18.5% downside | |
| 2025-10-13 | NeedhamAmi Fadia | $28 | 36.6% downside | |
| 2025-03-07 | Robert W. Baird | $16 | 63.8% downside | |
| 2024-09-16 | Canaccord GenuitySumart Kulkami | $14 | 68.3% downside | |
| 2024-06-05 | RBC CapitalBrian Abrahams | $22 | 50.2% downside | |
| 2024-05-13 | OppenheimerFrancois Brisebois | $20 | 54.7% downside | |
| 2022-11-16 | RBC Capital | $5 | 88.7% downside | |